On 26 May 2022 the President of the Agency for Health Technology Assessment and Tariff System issued the following recommendation:
Recommendation No. 47/2022 of 26 May 2022 of the President of the Agency for Health Technology Assessment and Tariff System on the evaluation of Doptelet (awatrombopag) under the drug programme: “B.97. Treatment of adult patients with primary immune thrombocytopenic purpura (ICD-10: D69.3)”